Comprehensive cancer testing to turn uncertainty into clarity

Get the information you need to better inform treatment options.

CancerVision

Insights to support your doctor’s treatment decisions and personalized therapy selections based on your test findings and overall clinical profile.

Who is CancerVision for?

CancerVision is recommended by Oncologist to patients at any stage of treatment for diagnosed non-blood related cancers looking for more insights and possible treatment options.

CancerVision report includes:

A whole genome genetic test that looks at your genes for a comprehensive view of your cancer cells
Insights to support your doctor’s treatment decisions and personalized therapy selections based on your test findings

Clinical trial matching support for certain cancers based off your unique biomarkers and your other medical implications
2-week turnaround time*

*2 weeks from receipt of your tissue and blood samples at our lab.

More than a quarter of cancer patients¹ have complicated genetic mutations that are often missed by other tests. CancerVision uses whole genome testing designed to help uncover critical information that other tests could have missed.

Whole genome coverage

Standard panel genetic testing for cancer looks at less than 0.1% of the genome², leaving lots of room for unanswered questions. CancerVision provides an extensive analysis of the cancer genomic makeup to give your healthcare provider more detailed information about your cancer.

Easy-to-understand reports

After testing, your health care provider will receive a report that is detailed and easy to understand. It provides insights about your cancer and known mutations to help you and your healthcare provider make informed decisions.

Clinical trial matching support

Only 8%³ of eligible cancer patients are enrolled in clinical trials in the US. We identify clinical trial matches based on your biomarkers and additional criteria.

Lung cancer diagnosis informs a successful treatment regimen

Steven, 70, had a cancerous mass removed from his small intestine but lacked answers about where his primary tumor was located. CancerVision was ordered to help clarify the origin of the primary cancer and to confirm a diagnosis. The test discovered a tobacco-related molecular signature that led to a diagnosis of metastatic non-small cell lung cancer. This known gene mutation was used to develop a medical care plan and treatment strategies for Steven that led to consistent progress.

Breast cancer patient finds improved health with clinical trial

Sarah, 52, was diagnosed with stage IV breast cancer and wasn’t responding to immunotherapy or chemo treatments. Her provider ordered a CancerVision test, which pinpointed a genetic structural change in Sarah’s RAD51C gene. This mutated gene wasn’t found by other types of genetic tests. This finding led to the decision to enroll her in a clinical trial for a new drug, which has since improved her health.

Shedding light on cancer’s hereditary nature

Emily, 40, was diagnosed with breast cancer after receiving a sarcoma diagnosis at a young age. Her oncologist ordered CancerVision, which uncovered a genetic mutation in her TP53 gene. This finding led to a diagnosis of Li-Fraumeni syndrome, which is associated with a high cancer risk. This gene mutation was not detected in other panel tests, yet it provided Emily’s physician with a better understanding of the nature of her hereditary cancer. This led to testing her sibling to get a better understanding of how cancer may affect her other family members and whether they were at increased risk of developing cancer.

**While all patient names provided are fictionalized to ensure privacy and confidentiality, the age, disease information, and diagnostic process in the testimonials are based on real cases. Please note that clinical outcomes may vary for each individual. Stock photo used to protect patient privacy.

How can I order a test?

CancerVision tests are ordered by your health care provider at their discretion based on patient symptoms and medical history.

Is the test covered by health insurance?

Currently, our whole genome sequencing medical tests are not yet covered by health insurance in the US. We are working on insurance coverage to provide easy access to all patients.

Outside of the US, our products may be covered by insurance, but it varies significantly by the country and types of insurance. We suggest reaching out to your insurer to confirm. If you need any support exploring it, please contact us at inquiry@inocras.com.